Advertisement

Drug Prices and Incentives to Innovation by the Pharmaceutical Industry

  • Rosella LevaggiEmail author
  • Paolo Pertile
Chapter

Abstract

In the recent past, pharmaceutical expenditure has been steadily increasing, but the productivity of the sector—measured as the number of New Molecular Entities (NMEs)—has been decreasing. In this chapter we review and analyse the price regulation policies that are currently used by regulators worldwide and we will describe the salient features of these policies from a public health point of view. We will also discuss this in terms of their impact on innovation.

Keywords

Consumer Surplus Reference Price Expected Profit Risk Sharing Price Regulation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, Laius O, Jan S, Sermet C, Zara C, Kalaba M, Gustafsson R, Garuoliene K, Haycox A, Garattini S, Gustafsson L (2010) Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res 10(1):153, ISSN 1472-6963. doi: 10.1186/1472-6963-10-153. http://www.biomedcentral.com/1472-6963/10/153
  2. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K (2009) Searching for cost effectiveness thresholds in the NHS. Health Policy 91(3):239–245, ISSN 0168-8510. doi:http://dx.doi.org/10.1016/j.healthpol.2008.12.010. http://www.sciencedirect.com/science/article/pii/S0168851008002911
  3. Barigozzi F, Levaggi R (2008) Emotions in physician agency. Health Policy 88(1):1–14CrossRefGoogle Scholar
  4. Barros PP (2011) The simple economics of risk sharing agreements between the NHS and the pharmaceutical industry. Health Econ 20(4):461–470CrossRefGoogle Scholar
  5. Barros PP, Levaggi R (2011) Searching for approval: risk sharing as price discount? MimeoGoogle Scholar
  6. Capri S, Levaggi R (2007) International price regulations in the pharmaceutical sector: a common model to sharing cost and benefits. J Pharmaceut Finance Econ Pol 15(2):21–40CrossRefGoogle Scholar
  7. Carone G, Schwierz C, Xavier A (2012) Cost-containment policies in public pharmaceutical spending in the EU. Technical report, European Commission-Economic and Financial AffairsGoogle Scholar
  8. Cook J, Vernon J, Mannin R (2008) Pharmaceutical risk-sharing agreements. Pharmacoeconomics 26:551–556. doi: 10.2165/00019053-200826070-00002 CrossRefGoogle Scholar
  9. Danzon PM, Chao L-W (2000) Does regulation drive out competition in pharmaceutical markets? J Law Econ 43(2):311–357CrossRefGoogle Scholar
  10. Danzon P, Towse A, Mestre-Ferrandiz J (2013) Value-based differential pricing: efficient prices for drugs in a global context. Health Econ. doi: 10.1002/hec.3021
  11. De Pouvourville G (2006) Risk-sharing agreements for innovative drugs. Eur J Health Econ 7:155–157, ISSN 1618-7598. http://dx.doi.org/10.1007/s10198-006-0386-6.10.1007/s10198-006-0386-6
  12. Dickson M, Redwood H (1998) Pharmaceutical reference prices: how do they work in practice? Pharmacoeconomics 14(5):471–479, http://www.ingentaconnect.com/content/adis/pec/1998/00000014/00000005/art00002
  13. DiMasi JA, Hansen RW, Grabowski HG (2003) The price of innovation: new estimates of drug development costs. J Health Econ 22(2):151–185, http://ideas.repec.org/a/eee/jhecon/v22y2003i2p151-185.html
  14. Dulleck U, Kerschbamer R (2006) On doctors, mechanics, and computer specialists: the economics of credence goods. J Econ Lit 44(1):5–42CrossRefGoogle Scholar
  15. Filson D (2012) A Markov-perfect equilibrium model of the impacts of price controls on the performance of the pharmaceutical industry. RAND J Econ 43(1):110–138CrossRefGoogle Scholar
  16. Gravelle HSE (1998) Ex post value reimbursement for pharmaceuticals. Med Decis Making 18(2):S27–S38. doi: 10.1177/0272989X9801800206. http://mdm.sagepub.com/content/18/2/S27.abstract
  17. Griffin SC, Claxton KP, Palmer SJ, Sculpher MJ (2011) Dangerous omissions: the consequences of ignoring decision uncertainty. Health Econ 20(2):212–224, ISSN 1099-1050. doi: 10.1002/hec.1586
  18. Jena AB, Philipson T (2008) Cost-effectiveness analysis and innovation. J Health Econ 27(5):1224–1236CrossRefGoogle Scholar
  19. Jena A, Philipson T (2009) Endogenous cost-effectiveness analysis in health care technology adoption. Working paper 15032, National Bureau of Economic Research, June 2009Google Scholar
  20. Lakdawalla D, Sood N (2009) Innovation and the welfare effects of public drug insurance. J Public Econ 93(3–4):541–548CrossRefGoogle Scholar
  21. Levaggi R (2014) Pricing schemes for new drugs: a welfare analysis. Soc Sci Med 102:69–73, ISSN 0277-9536. doi:http://dx.doi.org/10.1016/j.socscimed.2013.11.048. http://www.sciencedirect.com/science/article/pii/S0277953613006606
  22. Levaggi R, Moretto M, Pertile P (2013) The dynamics of pharmaceutical regulation and R&D investments. Working papers 13/2013, Department of Economics, University of Verona, Aug 2013. http://ideas.repec.org/p/ver/wpaper/13-2013.html
  23. Loeb M, Magat WA (1979) A decentralized method for utility regulation. J Law Econ 22(2):399–404, ISSN 00222186. http://www.jstor.org/stable/725125
  24. NICE (2007) Final appraisal determination bortezomib monotherapy for relapsed multiple myeloma. Accessed 3 Mar 2010Google Scholar
  25. OECD (2011) Health at a glance 2011: OECD indicators. Technical report, OECDGoogle Scholar
  26. OECD (2013) Health at a glance 2013: OECD indicators. OECD. http://dx.doi.org/10.1787/health_glance-2013-en
  27. Pammolli F, Magazzini L, Riccaboni M (2011) The productivity crisis in pharmaceutical R&D. Nat Rev Drug Discov 10(6):428–438, ISSN 1474–1776CrossRefGoogle Scholar
  28. Panos K, Taylor D, Manning J, Carr M (2010) Implementing value-based pricing for pharmaceuticals in the UK. http://www.2020Health.org
  29. PhRMA (2011) Annual report 2011. Technical report, PhRMA. http://www.phrma.org/sites/default/files/159/phrma_2011_annual_report.pdf
  30. Towse A, Garrison L (2010) Can’t get no satisfaction? Will pay for performance help? Toward an economic framework for understanding performance-based risk sharing agreements for innovative medical products. Pharmacoeconomics 28:93–102. doi: 10.2165/11314080-000000000-00000 CrossRefGoogle Scholar
  31. Zaric GS, O’Brien BJ (2005) Analysis of a pharmaceutical risk sharing agreement based on the purchaser’s total budget. Health Econ 14(8):793–803, ISSN 1099-1050. doi: 10.1002/hec.976. http://dx.doi.org/10.1002/hec.976
  32. Zweifel P, Breyer F, Kifmann M (2009) Health economics, 2nd edn. Springer, Berlin. ISBN 978-3-540-27804-7CrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.Department of Economics and ManagementUniversity of BresciaBresciaItaly
  2. 2.Department of EconomicsUniversity of VeronaVeronaItaly

Personalised recommendations